The role of MCT1 in tumor progression and targeted therapy: a comprehensive review
Overexpression of monocarboxylate transporter 1 (MCT1) in tumor cells is often associated with poor prognosis. The established mechanisms through which MCT1 and its mediated lactate transport drive tumor progression are manifold. The classical mechanisms include fostering metabolic symbiosis among t...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1610466/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850117724206792704 |
|---|---|
| author | Zheng Xu Xuemei Wang Hongjing Cheng Jiuling Li Xin Zhang Xueju Wang |
| author_facet | Zheng Xu Xuemei Wang Hongjing Cheng Jiuling Li Xin Zhang Xueju Wang |
| author_sort | Zheng Xu |
| collection | DOAJ |
| description | Overexpression of monocarboxylate transporter 1 (MCT1) in tumor cells is often associated with poor prognosis. The established mechanisms through which MCT1 and its mediated lactate transport drive tumor progression are manifold. The classical mechanisms include fostering metabolic symbiosis among tumor cells, dampening the immune function of immune cells, and spurring tumor angiogenesis. Beyond these, new findings of MCT1’s role in tumor progression have emerged. These new findings highlight MCT1’s involvement in mediating the reverse Warburg effect, inhibiting ferroptosis, promoting protective autophagy, and augmenting tumor glycolysis. When acetate serves as a transport substrate for MCT1, additional mechanisms come into play. These encompass MCT1’s participation in the acetylation of histone H3K27 and its role in upregulating c-Myc levels. Several studies have demonstrated that while selective MCT1 inhibitors can effectively impede tumor progression, they also face notable challenges. To address these, combining MCT1 inhibitors with other drugs appears to hold more promise. |
| format | Article |
| id | doaj-art-1151377e75a54f7b803c4e27509d8b82 |
| institution | OA Journals |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-1151377e75a54f7b803c4e27509d8b822025-08-20T02:36:02ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-06-011610.3389/fimmu.2025.16104661610466The role of MCT1 in tumor progression and targeted therapy: a comprehensive reviewZheng XuXuemei WangHongjing ChengJiuling LiXin ZhangXueju WangOverexpression of monocarboxylate transporter 1 (MCT1) in tumor cells is often associated with poor prognosis. The established mechanisms through which MCT1 and its mediated lactate transport drive tumor progression are manifold. The classical mechanisms include fostering metabolic symbiosis among tumor cells, dampening the immune function of immune cells, and spurring tumor angiogenesis. Beyond these, new findings of MCT1’s role in tumor progression have emerged. These new findings highlight MCT1’s involvement in mediating the reverse Warburg effect, inhibiting ferroptosis, promoting protective autophagy, and augmenting tumor glycolysis. When acetate serves as a transport substrate for MCT1, additional mechanisms come into play. These encompass MCT1’s participation in the acetylation of histone H3K27 and its role in upregulating c-Myc levels. Several studies have demonstrated that while selective MCT1 inhibitors can effectively impede tumor progression, they also face notable challenges. To address these, combining MCT1 inhibitors with other drugs appears to hold more promise.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1610466/fullMCT1oncogenic mechanismtumor progressionMCT1 inhibitortargeted therapy |
| spellingShingle | Zheng Xu Xuemei Wang Hongjing Cheng Jiuling Li Xin Zhang Xueju Wang The role of MCT1 in tumor progression and targeted therapy: a comprehensive review Frontiers in Immunology MCT1 oncogenic mechanism tumor progression MCT1 inhibitor targeted therapy |
| title | The role of MCT1 in tumor progression and targeted therapy: a comprehensive review |
| title_full | The role of MCT1 in tumor progression and targeted therapy: a comprehensive review |
| title_fullStr | The role of MCT1 in tumor progression and targeted therapy: a comprehensive review |
| title_full_unstemmed | The role of MCT1 in tumor progression and targeted therapy: a comprehensive review |
| title_short | The role of MCT1 in tumor progression and targeted therapy: a comprehensive review |
| title_sort | role of mct1 in tumor progression and targeted therapy a comprehensive review |
| topic | MCT1 oncogenic mechanism tumor progression MCT1 inhibitor targeted therapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1610466/full |
| work_keys_str_mv | AT zhengxu theroleofmct1intumorprogressionandtargetedtherapyacomprehensivereview AT xuemeiwang theroleofmct1intumorprogressionandtargetedtherapyacomprehensivereview AT hongjingcheng theroleofmct1intumorprogressionandtargetedtherapyacomprehensivereview AT jiulingli theroleofmct1intumorprogressionandtargetedtherapyacomprehensivereview AT xinzhang theroleofmct1intumorprogressionandtargetedtherapyacomprehensivereview AT xuejuwang theroleofmct1intumorprogressionandtargetedtherapyacomprehensivereview AT zhengxu roleofmct1intumorprogressionandtargetedtherapyacomprehensivereview AT xuemeiwang roleofmct1intumorprogressionandtargetedtherapyacomprehensivereview AT hongjingcheng roleofmct1intumorprogressionandtargetedtherapyacomprehensivereview AT jiulingli roleofmct1intumorprogressionandtargetedtherapyacomprehensivereview AT xinzhang roleofmct1intumorprogressionandtargetedtherapyacomprehensivereview AT xuejuwang roleofmct1intumorprogressionandtargetedtherapyacomprehensivereview |